Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838579 | 0.79 | RET (0.58) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL5548145 | 0.76 | RET (0.46) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL3439134 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL130234 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL29843330 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL24115843 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL29367518 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL3362960 | 0.75 | RET (0.77) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL69430 | 0.74 | PARP1 (0.48) | RETKDRSTK17BADORA3CYP19A1 | |
| SCHEMBL1429502 | 0.74 | STK17B (0.46) | RETKDRSTK17BADORA3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211725-B2 | Inkjet recording method and printed material | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9211725-B2 | Inkjet recording method and printed material | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2682272-B1 | INK JET RECORDING METHOD AND PRINTED MATERIAL | FUJIFILM CORP (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2085439-B1 | Photocurable composition, photocurable ink composition, process for producing photocured material, and inkjet recording method | FUJIFILM CORP (JP) | 2013-10-02 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8378002-B2 | Aqueous ink composition, aqueous ink composition for inkjet recording, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8378002-B2 | Aqueous ink composition, aqueous ink composition for inkjet recording, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8168263-B2 | Photo-curable composition, ink composition, and inkjet recording method using the ink composition | FUJIFILM CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168263-B2 | Photo-curable composition, ink composition, and inkjet recording method using the ink composition | FUJIFILM CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20080182031-A1 | Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound | FUJIFILM CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080182031-A1 | Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound | FUJIFILM CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6689798-B2 | STEROID ALPHA-HYDROXYLASE AND STEROID LYASE INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-10 | — | — | US | disclosed |
| US-20030149079-A1 | Novel benzofuran derivatives | DAIICHI PHARMACEUTICAL CO., LTD. | 2003-08-07 | — | — | US | disclosed |
| EP-1283208-A1 | NOVEL BENZOFURAN DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-0020266-A1 | Derivatives of cyano-2-hydroxy-3-benzofurane and benzo(b)thiophene, their preparation and their use in therapy | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1980-12-10 | — | — | EP | disclosed |
| EP-0020266-A1 | Derivatives of cyano-2-hydroxy-3-benzofurane and benzo(b)thiophene, their preparation and their use in therapy | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149079-A1 | Novel benzofuran derivatives | CYP17A1, CYP21A2, HSD17B7 | RET 3465/4885KDR 3822/4885STK17B 1067/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | RET 957/4885KDR 3886/4885STK17B 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.